Skip to content
ChickenStockChickenStock
ResearchELVN
Enliven Therapeutics logo

Enliven Therapeutics (ELVN) stock

NASDAQ

$46.80-1.72%(-0.82)

As of the Nov 17, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-30.38x

Net loss — not comparable

P/B

3.95x

P/S

—

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Operating income decreased from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 5, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

38 SEC filings
  • Kunkel Lori AnneDirector · Oct 30, 2026Option exercise11,041 shares · $138K
    Avg. price $12.4789
    Show 2 price lots
    • 7,300 shares × $18.3$134K
    • 3,741 shares × $1.12$4K
  • Hohl BenjaminCHIEF FINANCIAL OFFICER · Oct 19, 2026Open-market sale6,018 shares · $232K
    Avg. price $38.475538,000 shares held after
  • Collins Helen LouiseCHIEF MEDICAL OFFICER · Oct 19, 2026Open-market sale5,000 shares · $192K
    Avg. price $38.468425,000 shares held after
  • Hohl BenjaminCHIEF FINANCIAL OFFICER · Oct 19, 2026Option exercise6,018 shares · $89K
    Avg. price $14.8544,018 shares held after
  • Collins Helen LouiseCHIEF MEDICAL OFFICER · Oct 19, 2026Option exercise5,000 shares · $12K
    Avg. price $2.4830,000 shares held after
  • Garland J. ScottDirector · Oct 1, 2026Open-market sale13,000 shares · $607K
    Avg. price $46.67070 shares held after
  • Garland J. ScottDirector · Oct 1, 2026Option exercise13,000 shares · $201K
    Avg. price $15.4713,000 shares held after
  • Hohl BenjaminCHIEF FINANCIAL OFFICER · Sep 17, 2026Open-market sale6,018 shares · $303K
    Avg. price $50.3495
    Show 3 price lots
    • 3,535 shares × $50.0286$177K
    • 2,194 shares × $50.7158$111K
    • 289 shares × $51.4929$15K
  • Collins Helen LouiseCHIEF MEDICAL OFFICER · Sep 17, 2026Open-market sale5,000 shares · $252K
    Avg. price $50.3508
    Show 3 price lots
    • 2,916 shares × $50.0312$146K
    • 1,844 shares × $50.7089$94K
    • 240 shares × $51.482$12K
  • Hohl BenjaminCHIEF FINANCIAL OFFICER · Sep 17, 2026Option exercise3,982 shares · $59K
    Avg. price $14.8544,018 shares held after
  • Collins Helen LouiseCHIEF MEDICAL OFFICER · Sep 17, 2026Option exercise5,000 shares · $12K
    Avg. price $2.4830,000 shares held after
  • Hohl BenjaminCHIEF FINANCIAL OFFICER · Aug 17, 2026Open-market sale6,018 shares · $353K
    Avg. price $58.5828
    Show 2 price lots
    • 4,630 shares × $58.3517$270K
    • 1,388 shares × $59.3536$82K
  • Collins Helen LouiseCHIEF MEDICAL OFFICER · Aug 17, 2026Open-market sale5,000 shares · $293K
    Avg. price $58.5862
    Show 2 price lots
    • 3,900 shares × $58.3717$228K
    • 1,100 shares × $59.3465$65K
  • Collins Helen LouiseCHIEF MEDICAL OFFICER · Aug 17, 2026Option exercise5,000 shares · $12K
    Avg. price $2.4830,000 shares held after
  • Derynck Mika KDirector · Aug 4, 2026Open-market sale158,795 shares · $9.6M
    Avg. price $60.21340 shares held after
  • Derynck Mika KDirector · Aug 4, 2026Option exercise158,795 shares · $1.7M
    Avg. price $10.8377
    Show 4 price lots
    • 27,567 shares × $25.28$697K
    • 20,491 shares × $22.47$460K
    • 23,364 shares × $14.85$347K
    • 87,373 shares × $2.48$217K
  • Hohl BenjaminCHIEF FINANCIAL OFFICER · Jul 17, 2026Open-market sale6,018 shares · $317K
    Avg. price $52.6388
    Show 5 price lots
    • 2,638 shares × $53.3825$141K
    • 2,564 shares × $52.318$134K
    • 369 shares × $51.4823$19K
    • 324 shares × $49.9715$16K
    • 123 shares × $53.8716$7K
  • Collins Helen LouiseCHIEF MEDICAL OFFICER · Jul 17, 2026Open-market sale5,000 shares · $263K
    Avg. price $52.6747
    Show 5 price lots
    • 2,184 shares × $53.4199$117K
    • 2,063 shares × $52.3921$108K
    • 459 shares × $51.5466$24K
    • 231 shares × $50.0542$12K
    • 63 shares × $53.9208$3K
  • Collins Helen LouiseCHIEF MEDICAL OFFICER · Jul 17, 2026Option exercise5,000 shares · $12K
    Avg. price $2.4830,000 shares held after
  • Hohl BenjaminCHIEF FINANCIAL OFFICER · Jul 17, 2026Option exercise1,072 shares · $3K
    Avg. price $2.4852,072 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Enliven Therapeutics (ELVN) stock information

NASDAQ

Enliven Therapeutics (ELVN) is listed on NASDAQ. Its market capitalization is about $3.5B. On trailing-twelve-month earnings the P/E ratio is -30.38, and the P/B ratio is 3.95. Return on equity is -13%. These figures are computed in-house from official filings and are reference information only.

Enliven Therapeutics — frequently asked questions

What is the P/E ratio of Enliven Therapeutics (ELVN)?
On a trailing-twelve-month basis, ELVN trades at a P/E ratio of -30.38. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Enliven Therapeutics?
ELVN has a market capitalization of about $3.5B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.